Literature DB >> 23099333

Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka.

Rajiva de Silva1, Sunethra Gunasena, Damayanthi Ratnayake, G D Wickremesinghe, C D Kumarasiri, B A W Pushpakumara, Jagadish Deshpande, Anna Lea Kahn, Roland W Sutter.   

Abstract

BACKGROUND: The Global Polio Eradication Initiative, established in 1988, has made substantial progress toward achieving this target, with only 3 countries never having eliminated wild poliovirus. Persons with primary immune deficiency disorders (PIDD) exposed to OPV are at increased risk of vaccine-associated paralytic poliomyelitis (VAPP) and of prolonged excretion of Sabin polioviruses. However, the risk for prolonged excretion is not known. Therefore, we studied the prevalence of PIDD with long-term poliovirus excretion in Sri Lanka, a middle income country currently using OPV.
METHODS: We stimulated the referral of patients under the age of 35 years, with clinical features suggestive of immune deficiency to the single immunology clinic in the country, where these patients were investigated for the presence of PIDD. Stool samples from patients with PIDD were cultured for the presence of poliovirus (PV). Poliovirus isolates were tested for intratypic differentiation (ITD). The VP1 region of all poliovirus isolates was sequenced.
RESULTS: Of 942 patients investigated, 51 (5.4%) were diagnosed with PIDD. Five (10.2%) patients excreted poliovirus. A patient with X linked agammaglobulinemia (XLA) excreted a mixture of all three Sabin like (SL) poliovirus serotypes. One patient with severe combined immune deficiency (SCID) excreted SL type 2, and another with SCID excreted SL type 3. One patient with SCID excreted a P2 vaccine-derived poliovirus (VDPV 2), and another with common variable immune deficiency (CVID) excreted a VDPV 3. The 3 patients with SCID died before scheduled collection of subsequent samples one month later, while the patient with XLA had cleared the virus in stool sample collected after 3 and 11 months. The CVID patient with VDPV 3 excreted for 7 months, and has developed a 23 nucleotide divergence in VP1 (∼900 nucleotides) from the parental Sabin virus.
CONCLUSIONS: In our study, several patients with SCID, XLA and CVID excreted poliovirus. With improving health care quality patients with CVID and XLA may survive longer especially with provision of intravenous immune globulin. Regular screening of patients with PIDD for excretion of poliovirus is necessary to identify chronic excretors and make available specific therapies.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23099333     DOI: 10.1016/j.vaccine.2012.10.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity.

Authors:  Laura Pöyhönen; Jacinta Bustamante; Jean-Laurent Casanova; Emmanuelle Jouanguy; Qian Zhang
Journal:  J Clin Immunol       Date:  2019-05-23       Impact factor: 8.317

Review 2.  Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.

Authors:  Jean Guo; Sara Bolivar-Wagers; Nivedita Srinivas; Marisa Holubar; Yvonne Maldonado
Journal:  Vaccine       Date:  2015-01-16       Impact factor: 3.641

3.  Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication.

Authors:  Asghar Aghamohammadi; Hassan Abolhassani; Necil Kutukculer; Steve G Wassilak; Mark A Pallansch; Samantha Kluglein; Jessica Quinn; Roland W Sutter; Xiaochuan Wang; Ozden Sanal; Tatiana Latysheva; Aydan Ikinciogullari; Ewa Bernatowska; Irina A Tuzankina; Beatriz T Costa-Carvalho; Jose Luis Franco; Raz Somech; Elif Karakoc-Aydiner; Surjit Singh; Liliana Bezrodnik; Francisco J Espinosa-Rosales; Anna Shcherbina; Yu-Lung Lau; Shigeaki Nonoyama; Fred Modell; Vicki Modell; Mohamed-Ridha Barbouche; Mark A McKinlay
Journal:  Front Immunol       Date:  2017-06-13       Impact factor: 7.561

4.  A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.

Authors:  Diana Kouiavskaia; Zhaochun Chen; Eugenia Dragunsky; Olga Mirochnitchenko; Robert Purcell; Konstantin Chumakov
Journal:  J Clin Virol       Date:  2015-02-03       Impact factor: 3.168

5.  Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment.

Authors:  Beatriz T Costa-Carvalho; Kathleen E Sullivan; Patrícia M Fontes; Fernanda Aimé-Nobre; Isabela G S Gonzales; Elaine S Lima; Celso Granato; Maria Isabel de Moraes-Pinto
Journal:  J Clin Immunol       Date:  2018-07-14       Impact factor: 8.317

6.  Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995-2014.

Authors:  Mohammadreza Shaghaghi; Shohreh Shahmahmoodi; Hassan Abolhassani; Saeed Soleyman-Jahi; Leila Parvaneh; Sussan Mahmoudi; Zahra Chavoshzadeh; Reza Yazdani; Seyed Mohsen Zahraei; Mohsen Ebrahimi; Mohammad H Eslamian; Hamideh Tabatabaie; Maryam Yousefi; Yaghoob M Kandelousi; Aliasghar Oujaghlou; Nima Rezaei; Asghar Aghamohammadi
Journal:  Emerg Infect Dis       Date:  2016-10       Impact factor: 6.883

7.  Vaccine-associated paralytic poliomyelitis and BCG-osis in an immigrant child with severe combined immunodeficiency syndrome - Texas, 2013.

Authors:  Robert Trimble; Jane Atkins; Troy C Quigg; Cara C Burns; Gregory S Wallace; Mary Thomas; Anil T Mangla; Anthony J Infante
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-08-22       Impact factor: 17.586

8.  Poliovirus Excretion in Children with Primary Immunodeficiency Disorders, India.

Authors:  Madhu Chhanda Mohanty; Manisha Rajan Madkaikar; Mukesh Desai; Prasad Taur; Uma Prajwal Nalavade; Deepa Kailash Sharma; Maya Gupta; Aparna Dalvi; Snehal Shabrish; Manasi Kulkarni; Jahnavi Aluri; Jagadish Mohanrao Deshpande
Journal:  Emerg Infect Dis       Date:  2017-10       Impact factor: 6.883

9.  Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-09-17       Impact factor: 3.090

10.  Spectrum of primary immunodeficiency disorders in Sri Lanka.

Authors:  Nilhan Rajiva de Silva; Sepali Gunawardena; Damayanthi Rathnayake; Geethani Devika Wickramasingha
Journal:  Allergy Asthma Clin Immunol       Date:  2013-12-27       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.